Int J Heart Fail.
2024 Oct;6(4):176-178. 10.36628/ijhf.2024.0018.
The Impact of the Novel Sodium-Dependent Glucose Cotransporter 2 Inhibitor, Enavogliflozin, on Cardiac Reverse Remodeling in Heart Failure Patients With Type 2 Diabetes Mellitus: A Case Series
- Affiliations
-
- 1Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Korea
- 2Gachon Cardiovascular Research Institute, Gachon University, Incheon, Korea
- 3Division of Cardiovascular Disease, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea
- KMID: 2560786
- DOI: http://doi.org/10.36628/ijhf.2024.0018
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Diabetic Ketoacidosis Induced by Sodium-Glucose Cotransporter 2 Inhibitor
- Prevention of Major Adverse Cardiovascular and Renal Outcomes with Sodium-Glucose Cotransporter 2 Inhibitors
- Case of hyperosmolar hyperglycemic state by a sodium-glucose cotransporter 2 inhibitor
- Sodium-Glucose Cotransporter 2 Inhibitors for People with Type 1 Diabetes
- The Side Effects of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor
